Every 8-K that QHSLAB, INC (USAQ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow USAQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USAQ filings page.
QHSLab, Inc. reported unaudited results for the three and six months ended June 30, 2026, showing strong growth in its Integrated Service Program (ISP). In Q2 2026, ISP revenue rose 86.4% to $491,399, while total revenue increased 40.1% to $847,490. Gross profit was $589,784 and gross margin expanded to 69.6%. Operating income increased to $45,245, and net income was $38,030, compared with a net loss of $52,958 a year earlier.
For the first half of 2026, total revenue grew 26.0% to $1,576,175, with ISP revenue up 103.2% to $865,900, representing roughly 55% of revenue. Gross profit reached $1,060,587 and gross margin improved to 67.3%. Interest expense declined 87.3% to $16,741 following retirement of substantially all legacy convertible debt, and the net loss narrowed to $65,876 from $132,567. Management emphasized the growing recurring, software-enabled revenue base and lower financing costs as evidence of improving operating leverage.
QHSLab, Inc. filed a current report describing its participation in the Planet MicroCap Las Vegas 2026 conference at the Bellagio, held on June 16-18, 2026. Company representatives will give a corporate presentation, furnished as Exhibit 99.1, and hold one-on-one meetings with various professional and high-net-worth investors.
The presentations will cover QHSLab’s business, strategy, products, market opportunity, growth initiatives, and financial performance, with the goal of increasing investor awareness. The information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings except by specific reference.
QHSLab also highlights that it uses its website and several social media channels, including Twitter/X, LinkedIn, Facebook, and Instagram, to share information that may be considered material, encouraging investors to follow these outlets for updates.
QHSLab, Inc. shared a shareholder update highlighting strong recent operating trends and growth initiatives. Unaudited revenue for April 2026 was approximately $325,889, up from $207,538 in April 2025, representing about 57% year-over-year growth, driven by increasing use of its digital medicine platform and integrated service program.
The Company introduced the QHS Practice Access Network (PAN), a nationwide independent representative program intended to accelerate adoption of its Q-Connect platform by leveraging existing healthcare relationships for warm introductions to physician practices. QHSLab also plans to present at the 2026 Planet MicroCap Showcase on June 16–18, 2026, to expand investor awareness of its digital health strategy.
QHSLab, Inc. reported unaudited first quarter 2026 Integrated Service Program (ISP) revenue of approximately $370,000, up from $163,000 a year earlier, representing 127% year-over-year growth driven by expanding provider adoption of its recurring digital care model.
The company also launched Q-Connect GLP-1, an assessment and personalized health journeys program supporting patients using anti-obesity medications, including GLP-1 therapies, and broader cardiometabolic and behavioral health needs, extending its digital health platform for primary care and specialty practices.
QHSLab, Inc. reported a strong turnaround for fiscal 2025, with revenue rising to $2,691,741, about 26% higher than 2024. Growth was driven largely by its Integrated Service Program for primary care practices.
Gross profit increased to $1,810,849 and gross margin improved to 67.3%, showing a shift toward higher-margin digital health services. The company moved to net income of $457,417 from a prior-year net loss, helped by lower interest expense and a gain of about $1.15 million from extinguishing convertible debt.
QHSLab strengthened its balance sheet as cash rose to $636,157 and current liabilities fell from roughly $2.4 million to about $450,000 at year-end 2025. Integrated Service Program revenue grew 74% year-over-year to $1,121,134, while immunotherapy sales also increased, supporting a more diversified and scalable business model.
QHSLab, Inc. filed a current report describing that, on January 26, 2026, it issued a press release with preliminary unaudited 2025 financial results. The release, furnished as Exhibit 99.1, highlights strong revenue growth, expanding margins, and significant debt reduction, indicating improved sales performance, profitability, and balance sheet strength for 2025.
The company states that this information is provided under Regulation FD and is furnished rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced. QHSLab also notes that it uses its website and social media channels, along with press releases, to share business and financial information that may be considered material for investors.
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. Under this deal, QHSLab repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021 in the principal amount of $750,000. As of December 31, 2025, the outstanding principal and accrued interest on the note totaled $470,529.
In exchange for eliminating this debt, QHSLab issued 1,568,432 shares of its common stock, as directed by MedScience. The company states that its Chief Executive Officer, who is a minority shareholder and service provider to MedScience, did not receive any personal distribution or other consideration from the transaction. The note is now fully satisfied and of no further force or effect.
The company characterizes this transaction as simplifying its capital structure, removing a related-party debt obligation, and improving the clarity of its balance sheet and financial reporting. The shares were issued in a private, unregistered offering under Section 4(a)(2) and/or Regulation D of the Securities Act as non-cash consideration for cancellation of indebtedness.
QHSLab, Inc. reported that it issued a press release on January 16, 2026 announcing that it has initiated a board expansion process intended to strengthen corporate governance and support its next phase of growth. The press release is furnished as Exhibit 99.1 under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other SEC documents.
The company also reminds investors that it uses its website and social media accounts on Twitter, LinkedIn, Facebook, and Instagram, along with press releases, to share public information that could be considered material. The filing’s exhibit index lists the board expansion press release and the cover page interactive data file.
QHSLab, Inc. furnished an update under Regulation FD by issuing a press release titled “QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states that the information in the press release is furnished, not filed, under the Exchange Act and is not automatically incorporated into other filings unless specifically referenced. QHSLab also emphasizes its use of its website and social media channels, including Twitter, LinkedIn, Facebook, and Instagram, as additional ways to share business and financial information that may be considered material.
QHSLab, Inc. entered into a promissory note modification and partial conversion agreement with Alex Mirakian MD PA, converting $126,548 of principal and accrued interest into 421,827 common shares at an effective price of $0.30 per share. This reduced the outstanding balance on the original 10% convertible note to $20,000 and extended its maturity date to December 31, 2026. The remaining balance is still convertible at the holder’s option at a price equal to the greater of a 25% discount to the 15‑day average market price or $0.50 per share, and the company may prepay it at any time without penalty. The shares were issued as restricted securities in a private transaction relying on Section 4(a)(2) and Rule 506 of Regulation D, with no underwriters or commissions involved.
QHSLab, Inc. disclosed that on December 26, 2025 it closed a private placement with two accredited investors for approximately $500,000 of common stock and warrants. The company issued 1,666,663 shares of common stock at $0.30 per share and 416,666 warrants to purchase common stock.
Each warrant is exercisable at $0.60 per share and expires on December 31, 2030. Net proceeds to QHSLab were in excess of $495,000, with planned use for general corporate purposes, including working capital. The securities were issued in a private offering relying on Regulation D exemptions and were sold without brokers, underwriters, or finder fees.
QHSLab also noted it issued a press release on December 29, 2025 titled “QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure,” which was furnished as an exhibit.
QHSLab, Inc. reported that it has launched a new product called Q-Cog™, described as supporting early detection of mild cognitive impairment and dementia. The company disclosed this by issuing a press release titled “QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia,” which is furnished as an exhibit to this report under a Regulation FD disclosure item.
The company states that the press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporation into other filings unless specifically referenced. QHSLab also highlights that it uses its website and social media channels, along with press releases, to share information that could be considered important for investors.
QHSLab, Inc. filed a Form 8-K to announce that it has made its December 2025 corporate presentation available to the public. The presentation, dated December 1, 2025, provides information about the company’s business and operations and is included as Exhibit 99.1.
The disclosure is made under Regulation FD, which is intended to ensure that important company information is shared broadly and not selectively. QHSLab states that the information in this report and the exhibit is being furnished, not filed, meaning it is not subject to certain liability provisions. The company also highlights that investors and others can access potentially material information through its website, press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) filed an 8-K to furnish a shareholder letter under Regulation FD. On November 24, 2025, the company reported that it sent a letter to its shareholders, which is attached as Exhibit 99.1. The information in this exhibit is furnished under Item 7.01, meaning it is not considered “filed” for liability purposes under Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
The company reiterates that it has no obligation to update forward-looking statements. It also highlights that investors, media, and others may receive material information through its website (usaqcorp.com), press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) entered into a Note Repurchase Agreement on November 18, 2025 to buy back its outstanding defaulted convertible promissory notes. These notes, issued in 2021 and 2022, had an aggregate outstanding balance of principal and accrued interest in excess of $1.4 million and carried a default interest rate of 18 percent per annum. QHSLab repurchased the notes for a cash payment of $300,000, funded by operating cash and a short-term advance from its President and CEO. Following payment, the notes were fully cancelled, all related liens and obligations were terminated, and all conversion rights, including conversion into common stock at $0.20 per share, were eliminated. The company highlighted this transaction in a press release describing the completion of the repurchase of legacy debt and its impact on the capital structure.